RET and non-small cell lung carcinoma: Regardless of performance status, first-line systemic therapy for those patients with advanced NSCLC (even with brain metastases) and a RET fusion is often with either of the oral RET TKIs (selpercatinib or pralsetinib), especially since current evidence is limited and suggests mixed efficacy of immune checkpoint inhibitor monotherapy with an ORR of 6%156–158.